ADACT Medical’s Chief Regulatory Officer, Damien Bové, was recently interviewed by respected publication BusinessCann about the European Industrial Hemp Association (EIHA) responding to criticisms over its Novel Food Application studies.
When asked about recent biomedical research actives undertaken by the EIHA, Damien Bové told BusinessCann that ‘this was not an adverse event, but it could lead to adverse events down the line. So it’s an observed event.’
There is a ‘pretty significant margin of error’ for testing in rats in terms of how it relates to human metabolism, and that pharmaceutical studies often test on more than one animal ‘to see if you get the same effect’.
You can read the full interview with BusinessCann at: https://businesscann.com/eiha-responds-to-criticisms-over-its-novel-food-applications-tox-studies/
To discuss Novel Food Applications with ADACT, please call +44(0)1302 986 088 or email [email protected]